Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:13 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 25,190 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: PRE Clear all

Conditions: Multiple Myeloma, Relapse Multiple Myeloma, Refractory Multiple Myeloma
Interventions: Elranatamab, GM-CSF, DC/MM Fusion Vaccine; Drug · Biological
Lead sponsor: David Avigan; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Pancreatic Cancer, Adult, Prehabilitation
Interventions: Multimodal Prehabilitation; Behavioral
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Worester, Massachusetts

Conditions: HIV
Interventions: Condom choices, Condom-compatible lubricant choices, Couples HIV counseling and testing (CVCT), Pre-exposure prophylaxis with FTC/TDF, Staff and provider MSM and LGBT sensitization training, HIV Testing and Risk-reduction counseling, Linkage to care; Behavioral · Drug · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Atlanta, Georgia • Baltimore, Maryland

Conditions: Locally Advanced Breast Cancer, Metastatic Breast Cancer
Interventions: Fulvestrant, Exemestane; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 32 Years to 91 Years · Female only
Enrollment: 694 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2014
U.S. locations: 51
States / cities: Birmingham, Alabama • Arcadia, California • Fountain Valley, California + 48 more

Conditions: Pain
Interventions: Baclofen 10mg, Placebo; Drug · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Birth Asphyxia
Interventions: Umbilical Cord Milking, Early Cord Clamping; Procedure
Lead sponsor: Sharp HealthCare; Other
Eligibility: 35 Weeks to 42 Weeks
Enrollment: 1,730 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 7
States / cities: Davis, California • Loma Linda, California • San Diego, California + 3 more

Conditions: Vitiligo
Interventions: Ibuprofen; Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years to 90 Years
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Heart Failure NYHA Class II, Heart Failure NYHA Class III
Interventions: Reveal LINQ™ Insertable Cardiac Monitor with investigational ALLEVIATE-HF RAMware download, Medication intervention, Not Randomized to Device or Medication Intervention; Device · Other
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure; Industry
Eligibility: 18 Years and older
Enrollment: 826 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 53
States / cities: Mesa, Arizona • Jonesboro, Arkansas • Mission Viejo, California + 47 more

Conditions: Cancer, Pediatric Cancer
Interventions: Electronic educational material; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 25 Years
Enrollment: 89 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Hepatorenal Syndrome, Acute Kidney Injury
Interventions: R2R01, Terlipressin; Drug
Lead sponsor: River 2 Renal Corp.; Industry
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 7
States / cities: San Francisco, California • Atlanta, Georgia • Boston, Massachusetts + 4 more

Conditions: Plasma Cell Disorders
Interventions: Non-interventional study (observational); Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Relapsing Multiple Sclerorsis, Multiple Sclerosis, Primary Progressive
Interventions: Ocrelizumab, Lumbar Puncture, Methyloprednisolone, Antihistamine; Drug · Procedure
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 12
States / cities: Palo Alto, California • San Francisco, California • Aurora, Colorado + 9 more

Conditions: Hematologic Malignancy, Leukemia, Acute Lymphoblastic Leukemia, ALL, Acute Myelogenous Leukemia, AML, Chronic Lymphocytic Leukemia, CLL, Lymphoma, Hodgkin's Lymphoma, Non-hodgkin's Lymphoma, Myeloma
Interventions: Total Body Irradiation (TBI), Donor Lymphocyte Infusion (DLI), Cyclophosphamide (CY), Tacrolimus, Mycophenolate Mofetil (MMF), Hematopoietic Stem Cell Transplant (HSCT); Radiation · Biological · Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Congenital Heart Disease
Interventions: Angiotensin Converting Enzyme Inhibitor, No ACE Inhibitor; Drug · Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: Up to 17 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Smoking Cessation, Smoking, Nicotine Dependence
Interventions: Varenicline, Nicotine lozenge, Nicotine Patch; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 99 Years
Enrollment: 1,086 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 2
States / cities: Madison, Wisconsin • Milwaukee, Wisconsin

Conditions: Mild Cognitive Impairment
Interventions: Online Gameplay Intervention, Waitlist control; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 50 Years to 85 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Telemedicine
Interventions: Tool kit; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 336 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 4
States / cities: Orange, California • Boston, Massachusetts • Ann Arbor, Michigan + 1 more

Conditions: HIV
Interventions: Heart to Heart2 (HTH2); Behavioral
Lead sponsor: New York University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 512 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes Mellitus, Type 2
Interventions: Dario Blood Glucose Monitoring System, CDE; Device · Behavioral
Lead sponsor: LabStyle Innovations Ltd.; Industry
Eligibility: 35 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Feasterville, Pennsylvania

Conditions: Multiple Myeloma
Interventions: Daratumumab 16 mg/kg (Part 1), Daratumumab 8 mg/kg (Part 1), Methylprednisolone, Acetaminophen, Diphenhydramine, Daratumumab (Part 2); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 15
States / cities: Duarte, California • Los Angeles, California • Atlanta, Georgia + 12 more

Conditions: Suicide
Interventions: e-Connect; Behavioral
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 10 Years and older
Enrollment: 3,629 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Obesity
Interventions: Use of smartphone app; Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Breast Carcinoma, Breast Neoplasm
Interventions: Ultrasound; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Wound Infection
Interventions: Prevena, Traditional Dressing; Device
Lead sponsor: Englewood Hospital and Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Englewood, New Jersey

Search by objective public record fields.

A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma

Prehab for Pancreatic Cancer Surgery

Comprehensive HIV Prevention Package for MSM in Southern Africa: Pilot Study (Sibanye Health Project)

The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer

Baclofen as a Perioperative Analgesic Adjuvant

Umbilical Cord Milking in Non-Vigorous Infants

Effect of Combination Non Steroidal Antiinflammatory Drugs and Narrowband UVB Treatment in Non-Photoadapters

Algorithm Using LINQ Sensors for Evaluation And Treatment of Heart Failure

Education Tools to Support Pediatric Survivor Care

Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome

Gut Microbiome Studies in Patients With POEMS Syndrome and Other Plasma Cell Disorders

Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)

A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives

Angiotensin Converting Enzyme Inhibitors During Cardiopulmonary Bypass in Infants and Children

A Comparative Effectiveness & Long Term Health Study in Wisconsin Smokers

GAMES Intervention in MCI (Mild Cognitive Impairment)

The Actuate-CBC Study

Using MOST to Optimize an HIV Care Continuum Intervention for Vulnerable Populations

Digital Self-Management and Health Coaching for Type 2 Diabetes - Impact on Diabetes Clinical and Wellness Indicators

An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD

Scaling up e-Connect in Juvenile Probation Settings

Feasibility of Use of BariCare App in Pre-bariatric Surgery.

Quantitative Microvasculature Imaging for Breast Cancer Detection and Monitoring

Negative Pressure Therapy for Groin Wounds